AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31574581 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe uncorrected refractive error in Indigenous Australians
Number of subjects: 4836
Study 31574581 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (70-79 years) in Indigenous Australians
Number of subjects: 4836
Study 31574581 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in outer regional areas in Indigenous Australians
Number of subjects: 4836
Study 31574581 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having an eye examination in the previous 2 years in Indigenous Australians
Number of subjects: 4836
Study 31574581 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical remoteness in non-Indigenous Australians
Number of subjects: 4836
Study 31574581 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender in non-Indigenous Australians
Number of subjects: 4836
Study 31574581 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (70-79 years) in non-Indigenous Australians
Number of subjects: 4836
Study 31574581 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having an eye examination in the previous 2 years in non-Indigenous Australians
Number of subjects: 4836
Study 29446784 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaque sealant
Number of subjects: 42
Study 29446784 — intervention group
Group type: COMPARATOR
Intervention: Clear sealant
Number of subjects: 42
Study 28032151 — intervention group
Group type: EXPERIMENTAL
Intervention: Two septocolumellar sutures (Group-1)
Number of subjects: 44
Study 28032151 — intervention group
Group type: EXPERIMENTAL
Intervention: Columellar strut graft (Group-2)
Number of subjects: 44
Study 25958154 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (AliveCor) using position PI (horizontal)
Number of subjects: 37
Study 25958154 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (AliveCor) using position PII (rotated 60° clockwise)
Number of subjects: 37
Study 25958154 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (AliveCor) using position PIII (rotated 120° clockwise)
Number of subjects: 37
Study 25958154 — intervention group
Group type: COMPARATOR
Intervention: Comparison of position PII vs. PIII
Number of subjects: 37
Study 24293773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,630 m altitude exposure
Number of subjects: 51
Study 24293773 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,590 m altitude exposure
Number of subjects: 51
Study 24293773 — intervention group
Group type: COMPARATOR
Intervention: 490 m altitude exposure (control)
Number of subjects: 51
Study 21276534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Practice (MP) for 30 minutes before each laparoscopic cholecystectomy (LC)
Number of subjects: 20
Study 21276534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Practice (MP)
Number of subjects: 20
Study 21276534 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated activity)
Number of subjects: 20
Study 19221908 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized prevention programme
Number of subjects: 764
Study 19221908 — intervention group
Group type: COMPARATOR
Intervention: Usual classes
Number of subjects: 764
Study 17032123 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable membrane (RXT group)
Number of subjects: 16
Study 17032123 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (PG group)
Number of subjects: 16
Study 12595281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (Hypo; 100 mg/day spironolactone for 3 days)
Number of subjects: 8
Study 12595281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Normo)
Number of subjects: 8
Study 10992369 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 0
Study 10992369 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 10992369 — intervention group
Group type: EXPERIMENTAL
Intervention: General population
Number of subjects: 0
Study 10992369 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination
Number of subjects: 0
Study 10992369 — intervention group
Group type: EXPERIMENTAL
Intervention: Former PSA testing or digital rectal examination
Number of subjects: 0
Study 7671058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 30
Study 7671058 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study 2360466 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) as prophylactic treatment
Number of subjects: 128
Study 2360466 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of AEDs after surgery in patients with preoperative epilepsy
Number of subjects: 128
Study 2360466 — intervention group
Group type: EXPERIMENTAL
Intervention: No long-term AEDs treatment in patients without preoperative epilepsy
Number of subjects: 128
Study 7302369 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (5 mg)
Number of subjects: 9
Study 7302369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31126208 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP hydrogel
Number of subjects: 60
Study 31126208 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 60
Study 28288074 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA test results provided directly to patients
Number of subjects: 4525
Study 25887586 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck osteotomy guide
Number of subjects: 48
Study 25887586 — intervention group
Group type: COMPARATOR
Intervention: No femoral neck osteotomy guide
Number of subjects: 48
Study 23398608 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10 Hz, 20 min, total 2,000 pulses)
Number of subjects: 18
Study 23398608 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (20 min)
Number of subjects: 18
Study 21883158 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion norm
Number of subjects: 383
Study 21883158 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion norm
Number of subjects: 383
Study 21883158 — intervention group
Group type: COMPARATOR
Intervention: School inclusion norm
Number of subjects: 383
Study 21883158 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion-plus-relational aggression norm
Number of subjects: 383
Study 18498003 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 4351
Study 18498003 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 4351
Study 17597050 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily
Number of subjects: 50
Study 17597050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15114776 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravesicular immunotherapy with ronkoleucine 1,000,000 IU
Number of subjects: 30
Study 15114776 — intervention group
Group type: COMPARATOR
Intervention: Postoperative intravesicular immunotherapy with ronkoleucine 500,000 IU
Number of subjects: 30
Study 11407666 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary angioplasty + Helicobacter pylori eradication therapy
Number of subjects: 240
Study 11407666 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary angioplasty + placebo treatment
Number of subjects: 240
Study 11407666 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori seropositivity in coronary artery disease patients
Number of subjects: 240
Study 11407666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxin associated gene A IgG detection in coronary artery disease patients
Number of subjects: 240
Study 9728837 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine 2 mg/kg
Number of subjects: 65
Study 9185632 — intervention group
Group type: COMPARATOR
Intervention: Registry patients (CABG)
Number of subjects: 842
Study 9185632 — intervention group
Group type: COMPARATOR
Intervention: Registry patients (PTCA)
Number of subjects: 842
Study 9185632 — intervention group
Group type: COMPARATOR
Intervention: Randomized patients (CABG)
Number of subjects: 842
Study 9185632 — intervention group
Group type: COMPARATOR
Intervention: Randomized patients (PTCA)
Number of subjects: 842
Study 9185632 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry PTCA
Number of subjects: 842
Study 9185632 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry CABG
Number of subjects: 842
Study 2478336 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen
Number of subjects: 39
Study 2478336 — intervention group
Group type: COMPARATOR
Intervention: 500 mg naproxen
Number of subjects: 39
Study 2478336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 39
Study 968923 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (17‐ethinyl 1,3,5‐estratriene 3,17 diol)
Number of subjects: 82
Study 968923 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (90 mg estradiol valerianate and 300 mg 17‐hydroxy‐19‐norprogesterone caproate)
Number of subjects: 82
Study 968923 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 82
Study 968923 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 82
Study 31401786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (2403 mg/day)
Number of subjects: 1247
Study 31401786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study 28590143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise (CRAE) training for 12 weeks, 3 times per week
Number of subjects: 40
Study 25536215 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplant
Number of subjects: 150
Study 25536215 — intervention group
Group type: COMPARATOR
Intervention: No allogeneic hematopoietic cell transplant
Number of subjects: 150
Study 23537403 — intervention group
Group type: EXPERIMENTAL
Intervention: Legflow(®) paclitaxel eluting balloon with nitinol stenting
Number of subjects: 176
Study 23537403 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloon angioplasty with nitinol stenting
Number of subjects: 176
Study 21851167 — intervention group
Group type: EXPERIMENTAL
Intervention: Taprenepag isopropyl (0.0025%, 0.005%, 0.01%, 0.015%, 0.02%, 0.03%)
Number of subjects: 317
Study 21851167 — intervention group
Group type: EXPERIMENTAL
Intervention: Taprenepag isopropyl (0.005%, 0.01%, 0.015%) in unfixed combination with latanoprost 0.005%
Number of subjects: 317
Study 21851167 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 317
Study 21851167 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 317
Study 21851167 — intervention group
Group type: EXPERIMENTAL
Intervention: Taprenepag isopropyl (0.005%, 0.01%, 0.015%)
Number of subjects: 317
Study 21851167 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 317
Study 19419362 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking to the toilet (toilet group)
Number of subjects: 62
Study 19419362 — intervention group
Group type: COMPARATOR
Intervention: Using a bedpan (bedpan group)
Number of subjects: 62
Study 16394684 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg/kg)
Number of subjects: 40
Study 16394684 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 15763852 — intervention group
Group type: EXPERIMENTAL
Intervention: New curriculum with specified topics, a course book, and a case-based active learning session
Number of subjects: 614
Study 11165312 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview-based ratings of negative symptoms (measured by the Brief Psychiatric Rating Scale and the Positive and Negative Syndrome Scale)
Number of subjects: 35
Study 11165312 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview-based ratings of negative symptoms
Number of subjects: 35
Study 11165312 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based ratings of negative symptoms
Number of subjects: 35
Study 9051282 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapies for generalized anxiety disorder
Number of subjects: 0
Study 8369100 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day)
Number of subjects: 12
Study 8369100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3079992 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiocclusive dressings
Number of subjects: 0
Study 29743087 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (0.3 g/d)
Number of subjects: 100
Study 29743087 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (1.3 g/d)
Number of subjects: 100
Study 29743087 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+α‐LA (1.3 g/d + 0.3 g/d)
Number of subjects: 100
Study 29743087 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 29441923 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinal
Number of subjects: 31
Study 29441923 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (active control)
Number of subjects: 31
Study 29441923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 24503285 — intervention group
Group type: EXPERIMENTAL
Intervention: high-frequency rTMS to the right DLPFC
Number of subjects: 10
Study 24503285 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 22932325 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMTO LDV femtosecond laser with intended flap thickness of 90 µm
Number of subjects: 130
Study 22932325 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMTO LDV femtosecond laser with intended flap thickness of 110 µm
Number of subjects: 130
Study 22932325 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMTO LDV femtosecond laser
Number of subjects: 130
Study 19092847 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with quick lifting and slow lowering (ERT)
Number of subjects: 30
Study 19092847 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with slow lifting and quick lowering (CRT)
Number of subjects: 30
Study 19092847 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group (SED)
Number of subjects: 30
Study 17151341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus stimulation (n = 10)
Number of subjects: 20
Study 17151341 — intervention group
Group type: COMPARATOR
Intervention: Optimized medical treatment (n = 10)
Number of subjects: 20
Study 14726931 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rEpo) recipients
Number of subjects: 480
Study 14726931 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 480
Study 11590509 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART therapy (including indinavir or ritonavir or hard-gel saquinavir-containing regimens)
Number of subjects: 168
Study 9781603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg twice daily by mouth
Number of subjects: 31
Study 9781603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CF at 20 mg/m2 IV push, 5-FU at 325 mg/m2 IV daily for 5 days/week, and interferon alpha-2A 5 x 10(6) units/m2 SC on days 1, 3, 5
Number of subjects: 31
Study 7886777 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg aminosidine base/kg/d for 7 d
Number of subjects: 90
Study 7886777 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/kg/d for 14 d
Number of subjects: 90
Study 7886777 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg/kg/d for 14 d
Number of subjects: 90
Study 7886777 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 2963059 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol combined with ipratropium bromide
Number of subjects: 25
Study 2963059 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol alone
Number of subjects: 25
Study 6965579 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 10 mg orally every 6 hours
Number of subjects: 223
Study 6965579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 223
Study 31043773 — intervention group
Group type: EXPERIMENTAL
Intervention: semirigid thoracolumbar orthosis
Number of subjects: 15
Study 28560782 — intervention group
Group type: EXPERIMENTAL
Intervention: C3BS‐CQR‐1 (cardiopoietic mesenchymal stem cells)
Number of subjects: 351
Study 28560782 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 351
Study 25299463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 20
Study 25299463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23485605 — intervention group
Group type: EXPERIMENTAL
Intervention: Slight chamfer (CHA, n = 10)
Number of subjects: 90
Study 23485605 — intervention group
Group type: EXPERIMENTAL
Intervention: Knife-edge (KNE, n = 10)
Number of subjects: 90
Study 23485605 — intervention group
Group type: COMPARATOR
Intervention: Shoulder (SHO, n = 10, control)
Number of subjects: 90
Study 21378603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 338
Study 21378603 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet
Number of subjects: 338
Study 21378603 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study 19228754 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemofiltration
Number of subjects: 206
Study 19228754 — intervention group
Group type: COMPARATOR
Intervention: Haemodiafiltration
Number of subjects: 206
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting with GuardWire distal protection
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion (<2 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to reperfusion (2 to 3 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to reperfusion (>3 to 4 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to reperfusion (>4 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in anterior infarction (<2 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in anterior infarction (2 to 3 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in anterior infarction (>3 to 4 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in anterior infarction (>4 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in nonanterior infarction (<2 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in nonanterior infarction (2 to 3 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in nonanterior infarction (>3 to 4 hours)
Number of subjects: 501
Study 17560875 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time to reperfusion in nonanterior infarction (>4 hours)
Number of subjects: 501
Study 15379146 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC250 (lansoprazole 30 mg, amoxicillin 1000 mg, clarithromycin 250 mg)
Number of subjects: 235
Study 15379146 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC500 (lansoprazole 30 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Number of subjects: 235
Study 15379146 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC250
Number of subjects: 235
Study 15379146 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC500
Number of subjects: 235
Study 11451214 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (2.5-80 mg)
Number of subjects: 3095
Study 11451214 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (20 mg and above)
Number of subjects: 3095
Study 11451214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3095
Study 9714484 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia in patients with RCA lesion
Number of subjects: 60
Study 9714484 — intervention group
Group type: COMPARATOR
Intervention: Antegrade or retrograde cardioplegia in patients without RCA lesion
Number of subjects: 60
Study 9714484 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RCA lesion
Number of subjects: 60
Study 9714484 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of preoperative infarcts
Number of subjects: 60
Study 9714484 — intervention group
Group type: EXPERIMENTAL
Intervention: More advanced coronary artery disease
Number of subjects: 60
Study 9714484 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged stay in the intensive care unit
Number of subjects: 60
Study 9714484 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of postoperative ventricular tachycardia
Number of subjects: 60
Study 8066909 — intervention group
Group type: COMPARATOR
Intervention: Normal dose of budesonide via Nebuhaler
Number of subjects: 241
Study 8066909 — intervention group
Group type: EXPERIMENTAL
Intervention: Half normal dose of budesonide via Turbuhaler
Number of subjects: 241
Study 3058131 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol dry powder inhaled from Salbutamol cyclocaps Pharbita 0.4 mg
Number of subjects: 0
Study 3058131 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 0
Study 1126349 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of adaptiveness and appropriateness of mental retardation label by teachers
Number of subjects: 288
Study 31048638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Ahmed Glaucoma Valve (AGV) implantation and trabeculectomy revision with adjunctive antimetabolite
Number of subjects: 20
Study 31048638 — intervention group
Group type: COMPARATOR
Intervention: AGV implantation alone
Number of subjects: 20